Objective: To determine the effects of myo-inositol on oocyte quality in polycystic ovary syndrome (PCOS) patients undergoing intracytoplasmic sperm injection (ICSI) cycles.
Design: A prospective, controlled, randomized trial.
Setting: Assisted reproduction centers.
Patient(s): Sixty infertile PCO patients undergoing ovulation induction for ICSI.
Intervention(s): All participants underwent standard long protocol. Starting on the day of GnRH administration, 30 participants received myo-inositol combined with folic acid (Inofolic) 2 g twice a day and 30 control women received folic acid alone, administrated continuously.
Main Outcome Measure(s): Primary end points were number of morphologically mature oocytes retrieved, embryo quality, and pregnancy and implantation rates. Secondary end points were total number of days of FSH stimulation, total dose of gonadotropin administered, E2 level on the day of hCG administration, fertilization rate per number of retrieved oocytes, embryo cleavage rate, live birth and miscarriage rates, cancellation rate, and incidence of moderate or severe ovarian hyperstimulation syndrome.
Result(s): Total r-FSH units (1,958 695 vs. 2,383 578) and number of days of stimulation (11.4 0.9 vs. 12.4 1.4) were significantly reduced in the myo-inositol group. Furthermore, peak E2 levels (2,232 510 vs. 2,713 595 pg/mL) at hCG administration were significantly lower in patients receiving myo-inositol. The mean number of oocytes retrieved did not differ in the two groups, whereas in the group cotreated with myo-inositol the mean number of germinal vesicles and degenerated oocytes was significantly reduced (1.0 0.9 vs. 1.6 1.0), with a trend for increased percentage of oocytes in metaphase II (0.82 0.11% vs. 0.75 0.15%).
Conclusion(s): These data show that in patients with PCOS, treatment with myo-inositol and folic acid, but not folic acid alone, reduces germinal vesicles and degenerated oocytes at ovum pick-up without compromising total number of retrieved oocytes. This approach, reducing E2 levels at hGC administration, could be adopted to decrease the risk of hyperstimulation in such patients. (Fertil Steril 2009;91:1750–4.2009 by American Society for Reproductive Medicine.)
Key Words: Myo-inositol, oocyte quality, ovarian stimulation, ICSI cycles
Main Outcome Measure(s): Primary end points were number of morphologically mature oocytes retrieved, embryo quality, and pregnancy and implantation rates. Secondary end points were total number of days of FSH stimulation, total dose of gonadotropin administered, E2 level on the day of hCG administration, fertilization rate per number of retrieved oocytes, embryo cleavage rate, live birth and miscarriage rates, cancellation rate, and incidence of moderate or severe ovarian hyperstimulation syndrome.
Result(s): Total r-FSH units (1,958 ± 695 vs. 2,383 ± 578) and number of days of stimulation (11.4 ± 0.9 vs. 12.4 ± 1.4) were significantly reduced in the myo-inositol group. Furthermore, peak E2 levels (2,232 ± 510 vs. 2,713 ± 595 pg/mL) at hCG administration were significantly lower in patients receiving myo-inositol. The mean number of oocytes retrieved did not differ in the two groups, whereas in the group cotreated with myo-inositol the mean number of germinal vesicles and degenerated oocytes was significantly reduced (1.0 ± 0.9 vs. 1.6 ± 1.0), with a trend for increased percentage of oocytes in metaphase II (0.82 ± 0.11% vs. 0.75 ± 0.15%).
Conclusion(s): These data show that in patients with PCOS, treatment with myo-inositol and folic acid, but not folic acid alone, reduces germinal vesicles and degenerated oocytes at ovum pick-up without compromising total number of retrieved oocytes. This approach, reducing E2 levels at hGC administration, could be adopted to decrease the risk of hyperstimulation in such patients. (Fertil Steril± 2009;91:1750–4.2009 by American Society for Reproductive Medicine.)
Key Words: Myo-inositol, oocyte quality, ovarian stimulation, ICSI cycles